Bangladesh doctors urge Viagra production halt

September 26, 2012

Bangladeshi doctors Wednesday asked the government to halt permits for Viagra to be mass produced for the domestic market, fearing it could lead to the anti-impotence drug becoming available over the counter.

The government's Drug Control Committee recently granted licences to more than a dozen companies to make and market sildenafil citrate—better known as Viagra—in two forms, overturning a decade-long policy.

But the Bangladesh Medical Association, which represents the nation's 32,000 doctors, protested the decision, worried that the drug would effectively become available over the counter to people for whom it could carry .

"We want the government to cancel the licences because the drug, if it isn't prescribed by specialists, can seriously undermine ," its general secretary Sharfuddin Ahmed said.

The association will hold an emergency meeting to discuss the decision next week, Ahmed said, citing fears over a lack of regulation on drug sales.

"Anyone can buy any type of medicine over-the-counter at pharmacies here, even the drugs that are strictly meant to be prescribed by specialist physicians," he said.

The decision to grant licences came after a technical body argued that the number of people suffering from erectile dysfunction was increasing in the country, according to minutes of the committee meeting posted in its website.

At the moment, Viagra is not legally available for anyone in Bangladesh, even with a prescription.

"We have this month allowed some 13 to produce sildenafil citrate," Shah Ruhul Amin, an official of the government's drug administration, told AFP.

"Previously some firms were allowed to produce the drug only for export. But this time we've allowed it for the Bangladeshi market as experts opined in favour of its approval," he said.

Doctors have said misuse of sildenafil can lead to , , strike and diabetes.

Explore further: S. Korea to approve Viagra generics

Related Stories

S. Korea to approve Viagra generics

March 14, 2012
Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.

Thailand to sell generic Viagra drug: officials

September 26, 2012
Thailand has approved an affordable generic version of the anti-impotence drug Viagra to go on sale next week, as the country looks to combat rampant counterfeit production, officials said Wednesday.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.